Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A
出版年份 2023 全文链接
标题
Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A
作者
关键词
-
出版物
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-10-25
DOI
10.1111/ejh.14114
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A
- (2022) Sofie Persson et al. HAEMOPHILIA
- A multicentre real-world data study to assess the bleeding rate and management of patients with haemophilia A and factor VIII inhibitors in Argentina
- (2021) Daniela Neme et al. BLOOD COAGULATION & FIBRINOLYSIS
- Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes
- (2021) Haowei (Linda) Sun et al. HAEMOPHILIA
- Optimising prophylaxis in haemophilia A: The ups and downs of treatment
- (2021) Erik Berntorp et al. BLOOD REVIEWS
- Real-world treatment, clinical outcomes and healthcare resource utilization among persons with hemophilia A by age
- (2021) Eleanor O Caplan et al. Journal of Comparative Effectiveness Research
- Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
- (2021) Gili Kenet et al. Journal of Clinical Medicine
- Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
- (2020) Mark T. Reding et al. HAEMOPHILIA
- WFH Guidelines for the Management of Hemophilia, 3rd edition
- (2020) Alok Srivastava et al. HAEMOPHILIA
- A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients
- (2020) Songkai Yan et al. Journal of Managed Care & Specialty Pharmacy
- Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non‐interventional study in a real‐world setting
- (2019) Rebecca Kruse‐Jarres et al. HAEMOPHILIA
- Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study
- (2019) Johannes Oldenburg et al. BMJ Open
- BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
- (2019) Shadan Lalezari et al. HAEMOPHILIA
- Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial
- (2019) Elena Santagostino et al. THROMBOSIS RESEARCH
- Real-world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A
- (2018) A. L. Dunn et al. HAEMOPHILIA
- Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
- (2018) Lawrence Blonde et al. ADVANCES IN THERAPY
- Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII
- (2017) M. T. Reding et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc
- (2016) E. Berntorp et al. HAEMOPHILIA
- Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
- (2014) T. E. Coyle et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Modern haemophilia care
- (2012) Erik Berntorp et al. LANCET
- A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
- (2011) A. GRINGERI et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
- (2010) B. Mei et al. BLOOD
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started